Paul Tappenden

BA (Nottingham Trent), MSc (Sheffield), PhD (Sheffield)

Population Health, School of Medicine and Population Health

Professor of Health Economic Modelling
+44 114 222 0855

Full contact details

Paul Tappenden
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
S1 4DA

I have over 17 years’ experience in designing, developing and critically appraising health economic models across a wide range of disease areas. Since joining ScHARR in 2000, I have been involved in the assessment of numerous health technologies for the National Institute for Health and Care Excellence (NICE), including beta-interferon and glatiramer-acetate for multiple sclerosis, anti-TNFs for ulcerative colitis, inhaled therapies for cystic fibrosis and TKIs for medullary thyroid cancer. I have also undertaken modelling assessments for the National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre (NETSCC), the Advisory Group for National Specialised Services (AGNSS), the Department of Health and NHS Cancer Screening Programmes, including an options appraisal of colorectal cancer screening programmes. In 2011, I completed an NIHR-funded fellowship evaluating the role and value of health economic models of whole disease and treatment pathways (Whole Disease Modelling).

Research interests

My main research interests are:

  • Health economic modelling
  • Conceptual modelling
  • Whole disease modelling

Current projects

  • Technology assessments to inform the NICE Technology Appraisal Programme (various)
  • Economic analysis of interventions to improve adherence to nebulised therapies in patients with cystic fibrosis (alongside the CF ACtiF trial)
  • Modelling the potential cost-effectiveness of interventions for amyotrophic lateral sclerosis (part of the ALS-CARE study)

Show: Featured publications All publications

Journal articles

All publications

Journal articles


Conference proceedings papers

Scholarly editions

  • Claxton K, Eggington S, Ginnelly L, Griffin S, McCabe C, Philips Z, Tappenden P & Wailoo A A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Health and Clinical Excellence. RIS download Bibtex download
  • Tappenden P, Brazier J & Ratcliffe J Does the National Institute for Health and Clinical Excellence take account of factors such as uncertainty and equity as well as incremental cost-effectiveness in commissioning health care services? A binary choice experiment. RIS download Bibtex download


  • Rathbone J, Kaltenthaler E, Tappenden P, Bessey A & Cantrell A Issues in the systematic review of drugs for rare diseases: A case study of Eculizumab for AHUS (2012). RIS download Bibtex download
  • Harnan S, Essat M, Gomersall T, Tappenden P, Wong R, Lawson R, Pavord I & Everard M Exhaled nitric oxide for the diagnosis of asthma in children and adults: a systematic review. RIS download Bibtex download
  • Kaltenthaler E, Tappenden P & Paisley S Reviewing the evidence used in cost effectiveness models in health technology assessment: a qualitative investigation of current concerns. RIS download Bibtex download
  • Tappenden P, Brennan A, Chilcott J & Squires H Using Whole Disease Modelling to inform economic recommendations for the detection, diagnosis, treatment and followup of colorectal cancer. RIS download Bibtex download


Teaching activities
  • I am module lead for HAR691 (Using evidence in the design and development of models)
  • I am an active PhD supervisor (3 current PhD students)
Professional activities and memberships

I am the Director of Modelling for the ScHARR Technology Assessment Group and a member of the NICE Decision Support Unit (DSU). I am a member of NICE Technology Appraisal Committee C.